- Home
- MLR vs CVAC Comparison
MLR vs CVAC Comparison
Compare MLR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLR
- CVAC
- Stock Information
- Founded
- MLR 1990
- CVAC 2000
- Country
- MLR United States
- CVAC Germany
- Employees
- MLR N/A
- CVAC N/A
- Industry
- MLR Construction/Ag Equipment/Trucks
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MLR Consumer Discretionary
- CVAC Health Care
- Exchange
- MLR Nasdaq
- CVAC Nasdaq
- Market Cap
- MLR 769.3M
- CVAC 812.1M
- IPO Year
- MLR 1994
- CVAC 2020
- Fundamental
- Price
- MLR $67.91
- CVAC $4.10
- Analyst Decision
- MLR Strong Buy
- CVAC Hold
- Analyst Count
- MLR 1
- CVAC 3
- Target Price
- MLR $82.00
- CVAC $10.00
- AVG Volume (30 Days)
- MLR 72.5K
- CVAC 1.2M
- Earning Date
- MLR 03-05-2025
- CVAC 11-12-2024
- Dividend Yield
- MLR 1.12%
- CVAC N/A
- EPS Growth
- MLR 35.81
- CVAC N/A
- EPS
- MLR 6.02
- CVAC N/A
- Revenue
- MLR $1,331,839,000.00
- CVAC $70,565,734.00
- Revenue This Year
- MLR $16.10
- CVAC $742.57
- Revenue Next Year
- MLR $6.72
- CVAC N/A
- P/E Ratio
- MLR $11.28
- CVAC N/A
- Revenue Growth
- MLR 22.98
- CVAC 75.11
- 52 Week Low
- MLR $38.61
- CVAC $2.22
- 52 Week High
- MLR $78.25
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- MLR 52.25
- CVAC 62.06
- Support Level
- MLR $62.25
- CVAC $3.89
- Resistance Level
- MLR $67.77
- CVAC $4.32
- Average True Range (ATR)
- MLR 1.59
- CVAC 0.33
- MACD
- MLR 0.37
- CVAC 0.03
- Stochastic Oscillator
- MLR 82.03
- CVAC 54.27
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.